Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Berg

Showing results (461-470 of 632) with videos related to

Pageof 64
Sort By:
Cancer|July 17, 2015
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis BW Ray Kim, Rohit Loomba, Thomas Berg, et al.
Journal of Neuro-Oncology|January 27, 2020
Is the anatomical distribution of low-grade gliomas linked to regions of gliogenesis?Anne Jarstein Skjulsvik, Hans Kristian Bø, Asgeir Store Jakola, et al.
BMC Medical Informatics and Decision Making|August 13, 2024
Patient profiled data for treatment decision-making: valuable as an add-on to hepatitis C clinical guidelines?Sylvia M Brakenhoff, Thymen Theijse, Peter van Wijngaarden, et al.
Hepatology Communications|November 8, 2023
Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studiesTeerha Piratvisuth, Jinlin Hou, Tawesak Tanwandee, et al.
British Journal of Cancer|March 16, 2021
Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancerMehrdad Rakaee, Thomas K Kilvaer, Simin Jamaly, et al.
The New England Journal of Medicine|July 1, 2005
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis BGeorge K K Lau, Teerha Piratvisuth, Kang Xian Luo, et al.
Gastroenterology|April 19, 2006
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirinThomas Berg, Michael von Wagner, Samer Nasser, et al.
Hepatology (Baltimore, Md.)|January 12, 2012
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infectionJanett Fischer, Stephan Böhm, Markus Scholz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2020
Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis BMina S Farag, Margo J H van Campenhout, Maria Pfefferkorn, et al.
Journal of Hepatology|June 20, 2014
A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver diseaseHans Dieter Nischalke, Philipp Lutz, Benjamin Krämer, et al.
Pageof 64

Showing results (461-470 of 632) with videos related to

Sort By:
Pageof 64
Cancer|July 17, 2015
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis BW Ray Kim, Rohit Loomba, Thomas Berg, et al.
Journal of Neuro-Oncology|January 27, 2020
Is the anatomical distribution of low-grade gliomas linked to regions of gliogenesis?Anne Jarstein Skjulsvik, Hans Kristian Bø, Asgeir Store Jakola, et al.
BMC Medical Informatics and Decision Making|August 13, 2024
Patient profiled data for treatment decision-making: valuable as an add-on to hepatitis C clinical guidelines?Sylvia M Brakenhoff, Thymen Theijse, Peter van Wijngaarden, et al.
Hepatology Communications|November 8, 2023
Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studiesTeerha Piratvisuth, Jinlin Hou, Tawesak Tanwandee, et al.
British Journal of Cancer|March 16, 2021
Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancerMehrdad Rakaee, Thomas K Kilvaer, Simin Jamaly, et al.
The New England Journal of Medicine|July 1, 2005
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis BGeorge K K Lau, Teerha Piratvisuth, Kang Xian Luo, et al.
Gastroenterology|April 19, 2006
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirinThomas Berg, Michael von Wagner, Samer Nasser, et al.
Hepatology (Baltimore, Md.)|January 12, 2012
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infectionJanett Fischer, Stephan Böhm, Markus Scholz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2020
Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis BMina S Farag, Margo J H van Campenhout, Maria Pfefferkorn, et al.
Journal of Hepatology|June 20, 2014
A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver diseaseHans Dieter Nischalke, Philipp Lutz, Benjamin Krämer, et al.
Pageof 64